Hugues Dolgos

1.1k citations

26 papers · 792 indexed · h-index 16

Pharmacology top 1%
Oncology
Molecular Biology
Computational Theory and Mathematics top 5%
Spectroscopy top 10%

Co-authors: Sheila Annie Peters Carl PeterssonYan LiLars Weidolf J. Gerry Kenna Richard Weaver Richard A. Thompson Ian D. Wilson
Topics: Pharmacogenetics and Drug Metabolism (16 papers)Drug Transport and Resistance Mechanisms (8 papers)Computational Drug Discovery Methods (8 papers)
Cited by: Pharmacology Computational Theory and Mathematics Pharmaceutical Science
Journals: Journal of Clinical Oncology European Journal of Biochemistry Clinical Pharmacology & Therapeutics
Partner nations: Germany United States Sweden

In The Last Decade

Hugues Dolgos

26 papers receiving 761 citations

Peers

Countries citing papers authored by Hugues Dolgos

Since Specialization

Citations

This map shows the geographic impact of Hugues Dolgos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hugues Dolgos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hugues Dolgos more than expected).

Fields of papers citing papers by Hugues Dolgos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hugues Dolgos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hugues Dolgos. The network helps show where Hugues Dolgos may publish in the future.

Co-authorship network of co-authors of Hugues Dolgos

This figure shows the co-authorship network connecting the top 25 collaborators of Hugues Dolgos. A scholar is included among the top collaborators of Hugues Dolgos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hugues Dolgos. Hugues Dolgos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prediction of active human dose: learnings from 20 years of Merck KGaA experience, illustrated by case studies 2020 ·Drug Discovery Today ·Sheila Annie Peters,Carl Petersson,Andree Blaukat,Joern-Peter Halle,Hugues Dolgos	12
2	Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them 2019 ·Clinical Pharmacokinetics ·Sheila Annie Peters,Hugues Dolgos	55
3	Evaluating the Role of Solubility in Oral Absorption of Poorly Water‐Soluble Drugs Using Physiologically‐Based Pharmacokinetic Modeling 2019 ·Clinical Pharmacology & Therapeutics ·(unknown),Dajun Sun,(unknown),Melanie Schneider,(unknown),Hugues Dolgos,Karsten Mäder,(unknown)	55
4	Prediction of volume of distribution in humans: analysis of eight methods and their application in drug discovery 2019 ·Xenobiotica ·Carl Petersson,Orestis Papasouliotis,Marc Lecomte,Lassina Badolo,Hugues Dolgos	12
5	A comparative evaluation of models to predict human intestinal metabolism from nonclinical data 2017 ·Biopharmaceutics & Drug Disposition ·(unknown),Carl Petersson,Hugues Dolgos,Sheila Annie Peters	25
6	Translational Medicine Guide transforms drug development processes: the recent Merck experience 2016 ·Drug Discovery Today ·Hugues Dolgos,Mark Trusheim,Dietmar Groß,Joern-Peter Halle,(unknown),B Osterwalder,(unknown),(unknown)	42
7	Time- and NADPH-Dependent Inhibition of Cytochrome P450 3A4 by the Cyclopentapeptide Cilengitide: Significance of the Guanidine Group and Accompanying Spectral Changes 2014 ·Drug Metabolism and Disposition ·Mirza Bojić,(unknown),Hugues Dolgos,Achim Freisleben,(unknown),(unknown),F. Peter Guengerich	9
8	Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors 2013 ·Xenobiotica ·(unknown),Constanze Hilgendorf,Mareike Lutz,Philippe Bachellier,(unknown),(unknown),Hugues Dolgos,Lysiane Richert,A.‐L. Ungell	9
9	Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development 2013 ·Drug Metabolism and Disposition ·Fredrik Karlsson,(unknown),Constanze Hilgendorf,Hugues Dolgos,Sheila Annie Peters	31
10	Comparison of thein vitroandin vivometabolism of Cladribine (Leustatin, Movectro) in animals and human 2013 ·Xenobiotica ·(unknown),(unknown),(unknown),Ana Javornik,Hugues Dolgos	8
11	Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and Early Development 2012 ·Drug Metabolism and Disposition ·Sheila Annie Peters,Patricia Schroeder,Nagdeep Giri,Hugues Dolgos	38
12	The right compound in the right assay at the right time: an integrated discovery DMPK strategy 2012 ·Drug Metabolism Reviews ·Peter Ballard,Patrick Brassil,Khanh Bui,Hugues Dolgos,Carl Petersson,Anders Tunek,Peter J. H. Webborn	37
13	In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs 2012 ·Chemical Research in Toxicology ·Richard A. Thompson,Emre M. Isin,Yan Li,Lars Weidolf,Ken Page,Ian D. Wilson,Steve Swallow,Brian Middleton,Simone H. Stahl,Alison J. Foster,Hugues Dolgos,Richard Weaver,J. Gerry Kenna	153
14	In Vitro Characterization of Sarizotan Metabolism: Hepatic Clearance, Identification and Characterization of Metabolites, Drug-Metabolizing Enzyme Identification, and Evaluation of Cytochrome P450 Inhibition 2010 ·Drug Metabolism and Disposition ·(unknown),(unknown),(unknown),Achim Freisleben,Markus Fluck,B. Ladstetter,Hugues Dolgos	5
15	Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development 2010 ·Chemico-Biological Interactions ·Richard A. Thompson,Emre M. Isin,Yan Li,Richard Weaver,Lars Weidolf,Ian D. Wilson,Alf Claesson,Ken Page,Hugues Dolgos,J. Gerry Kenna	69
16	Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations 2009 ·Drug Discovery Today ·Johan Gabrielsson,Hugues Dolgos,Per‐Göran Gillberg,Ulf Bredberg,(unknown),Göran Duker	74
17	In Vitro and in Silico Identification and Characterization of Thiabendazole as a Mechanism-Based Inhibitor of CYP1A2 and Simulation of Possible Pharmacokinetic Drug-Drug Interactions 2009 ·Drug Metabolism and Disposition ·Roslyn Thelingwani,Simbarashe Zvada,Hugues Dolgos,Anna‐Lena Ungell,Collen Masimirembwa	21
18	Species Differences in the Response of Liver Drug-Metabolizing Enzymes to (S)-4-O-Tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric Acid (EMD 392949) in Vivo and in Vitro 2008 ·Drug Metabolism and Disposition ·Lysiane Richert,Gregor Tuschl,Catherine Viollon‐Abadie,Nadège Blanchard,Alexandre Bonet,Bruno Heyd,Nermin Halkic,(unknown),Hugues Dolgos,Stefan O. Mueller	23
19	Investigation of sarizotan’s impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial 2006 ·European Journal of Clinical Pharmacology ·Sonja Krösser,(unknown),Hugues Dolgos,Markus Fluck,(unknown),Andreas Kovar	23
20	Metabolism of Tentoxin by Hepatic Cytochrome P‐450 3A Isozymes 1997 ·European Journal of Biochemistry ·Marcel Delaforge,François André,Maryse Jaouen,Hugues Dolgos,Henri Bénech,(unknown),J. P. Noël,Florine Cavelier,Jean Verducci,Jean‐Louis Aubagnac,Bernd Liebermann	22

About Hugues Dolgos

Hugues Dolgos is a scholar working on Pharmacology, Computational Theory and Mathematics and Statistics and Probability, having authored 26 papers that have together received 792 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (16 papers), Drug Transport and Resistance Mechanisms (8 papers) and Computational Drug Discovery Methods (8 papers). The work is most often cited by research in Pharmacology (392 citations), Computational Theory and Mathematics (186 citations) and Pharmaceutical Science (53 citations). Hugues Dolgos has collaborated with scholars based in Germany, United States and Sweden. Frequent co-authors include Sheila Annie Peters, Carl Petersson, Yan Li, Lars Weidolf, J. Gerry Kenna, Richard Weaver, Richard A. Thompson, Ian D. Wilson, Emre M. Isin and Ken Page. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Biochemistry and Clinical Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact